Clinical Scorecard: Immediate Action Required to Tackle the Overdose Crisis Linked to Stimulants and Fentanyl
At a Glance
Category
Detail
Condition
Overdose crisis involving stimulants (cocaine, methamphetamine) contaminated with synthetic opioids (fentanyl and analogs)
Key Mechanisms
Unregulated drug supplies leading to fentanyl adulteration of stimulants, increasing risk of unintentional overdose
Target Population
People who use unprescribed stimulants, with disproportionate impact on Black and American Indian/Alaskan Native populations
Care Setting
Addiction treatment centers, primary care, mental health services, community health clinics, corrections facilities
Key Highlights
Marked increase in stimulant-related overdose deaths due to fentanyl contamination, especially in the US Northeast.
Rising stimulant use and stimulant-opioid co-use disproportionately affect minoritized populations, exacerbating overdose mortality disparities.
Evidence-based interventions like contingency management (CM) show promise but face implementation barriers outside select systems.
Guideline-Based Recommendations
Diagnosis
Optimize diagnosis of stimulant use disorder (StUD) with attention to co-use of opioids and fentanyl contamination risks.
Management
Implement and scale contingency management (CM) programs providing tangible rewards for stimulant abstinence.
Incorporate pharmacologic interventions alongside CM where appropriate.
Integrate peer, community, and family engagement in treatment plans.
Apply cultural adaptations and structural competency to reduce stigma and improve equity in care.
Monitoring & Follow-up
Monitor urine drug tests to verify abstinence in CM programs.
Track overdose trends and disparities among racial and ethnic groups to inform targeted interventions.
Risks
Unregulated stimulant supplies increase risk of fentanyl exposure and accidental overdose.
Treatment disparities due to stigma, implicit bias, and limited access to evidence-based care increase overdose risk in minoritized populations.
Patient & Prescribing Data
People with stimulant use disorder, particularly those at risk of fentanyl exposure and minoritized groups experiencing treatment disparities
CM is the most evidence-supported behavioral intervention for StUD but is underutilized due to insurance, regulatory, and funding barriers; culturally adapted CM programs may improve engagement and outcomes.
Clinical Best Practices
Incorporate structural competency education for providers to address systemic factors and reduce implicit bias.
Engage community, family, and cultural stakeholders in treatment planning to enhance cultural humility and relevance.
Expand harm reduction services tailored to stimulant and opioid co-use.
Advocate for policy reforms to increase funding and insurance coverage for CM and other evidence-based interventions.
Design CM programs with input from people with lived experience to ensure dignity and autonomy.
Chemsex at the pharmacy counter. Gut bacteria tracking helmet impacts. PMD predicting psychiatric illness bidirectionally. This week's research keeps landing in the same uncomfortable place: medicine is improvising.
